Surrozen Reports Q3 Financials, Advances Ophthalmology Pipeline

viernes, 7 de noviembre de 2025, 4:18 pm ET1 min de lectura
SRZN--

• Surrozen focuses on ophthalmology pipeline for severe eye diseases. • Lead candidates SZN-8141 and SZN-8143 in retina development. • Wnt biology expertise and antibody technologies used. • Third quarter financial results announced. • Business update provided.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios